5-10%of all cancers
are caused by inherited pathogenic gene mutations. If your family has multiple cancer diagnoses or early onset before age 50, hereditary predisposition is significantly more likely.
50+Syndromes
✓Full Screening
4 in 1Multi-omics
Hereditary Cancer Risk Prevention
$1,490
Evaluate your genetic cancer risks and safeguard your family. Comprehensive screening covering 50+ hereditary cancer syndromes.
Why Understanding Cancer Genetics is Critical
70%of women
with a BRCA1 or BRCA2 mutation develop breast cancer by age 80. Identifying this early enables surveillance and targeted risk-reducing strategies 10–15 years earlier.
80%of patients
with hereditary cancer identified at an early stage are successfully treated. For late-stage diagnoses, long-term survival drops below 30%.
5%of individuals
(1 in 20 people) carry pathogenic variants in hereditary cancer genes. Large population studies show that standard clinical guidelines miss over half of affected mutation carriers.
What Does Genetic Risk Knowledge Provide?
Personalized Checkup Protocols
Identify exactly which organs require intensified surveillance and at what intervals (e.g. annual breast MRI rather than standard ultrasound).
Actionable Cancer Prevention
For known hereditary syndromes, targeted surveillance, chemoprevention, and risk-reducing interventions substantially decrease cancer incidence and mortality.
Family Protection & Treatment Choice
Testing informs blood relatives (children, siblings) of cascade testing opportunities. For patients already diagnosed, results determine targeted PARP inhibitors and surgical scope.
Who Should Consider This Test
Family History of Cancer
Multiple cancer cases across generations or diagnoses before age 50 indicate genetic screening.
Proactive Prevention
Detecting elevated risk before onset, creating evidence-based screening schedules and lifestyle safeguards.
Diagnostic Clarification
Confirming suspected hereditary predisposition to optimize clinical staging and targeted systemic therapies.
Family Planning
Pre-conception genetic counseling to assess transmission risks of severe hereditary cancer predisposition.
What the Test Includes
Comprehensive multi-technology cancer genomics combining two state-of-the-art diagnostic platforms in a single workflow.
Whole Exome Sequencing (NGS)
Sequences all ~20,000 protein-coding genes simultaneously. Detects single nucleotide variants and small indels across 50+ actionable hereditary cancer genes.
Exon-Level Chromosomal Microarray (CMA)
Identifies large copy number variations (CNVs), deletions, and duplications that evade standard NGS sequencing, capturing an additional 5–10% of pathogenic variants.
Pharmacogenomics
Evaluates genetic variants affecting chemotherapy metabolism, toxicity (e.g. DPYD for 5-FU/capecitabine, UGT1A1 for irinotecan), and optimal analgesia.
DNA Archiving & Biobanking
Your constitutional DNA is extracted and cryopreserved under clinical biobank standards, allowing future updates and re-analysis without another sample collection.
Why Omninome Leads in Clinical Precision
OMNINOME Hereditary Cancer Panel
- ✓Dual-platform NGS Whole Exome + Exon-level CMA detects both point mutations and structural CNVs
- ✓Full pharmacogenomic profiling for oncology and supportive care included in the base package
- ✓Comprehensive coverage of 50+ hereditary cancer syndromes based on NCCN and ESMO standards
Standard Tests at Other Labs
- −Typically relies on a single sequencing technology, missing large structural rearrangements and exon deletions
- −Pharmacogenomics and toxicity risks require costly standalone add-on testing
- −Targeted narrow gene panels (e.g. 8–15 genes) leave other high-penetrance syndromes unexamined
Анализируем0генов
Screening spans all major high-penetrance hereditary cancer predispositions.
Hereditary Breast & Ovarian Cancer (HBOC)
Какие гены:
BRCA1BRCA2PALB2ATMCHEK2BARD1RAD51CRAD51D
Что может проявиться:
Breast, ovarian, pancreatic, and prostate cancer predisposition
Lynch Syndrome & Colorectal Cancer
Какие гены:
MLH1MSH2MSH6PMS2EPCAMAPCMUTYHSMAD4
Что может проявиться:
Colorectal, endometrial, gastric, and ovarian cancers
Li-Fraumeni & Multi-Organ Syndromes
Какие гены:
TP53PTENSTK11CDH1
Что может проявиться:
Sarcomas, brain tumors, diffuse gastric cancer, Cowden syndrome
Endocrine, Renal & Melanoma Syndromes
Какие гены:
RETMEN1VHLCDKN2ABAP1
Что может проявиться:
Multiple endocrine neoplasia, renal cell carcinoma, uveal & cutaneous melanoma
Clinical analysis is performed by certified bioinformaticians and medical geneticists in accordance with ACMG, AMP, and NCCN variant classification criteria. Полный список генов и заболеваний
Genetic testing results should always be interpreted in consultation with a board-certified geneticist or oncologist.
How the Process Works
1
Order Online
Order the test online. We dispatch a clinical collection kit or arrange a blood draw partner.
2
Sample Collection
Collect saliva or blood sample according to straightforward included instructions.
3
Laboratory Sequencing
High-depth Whole Exome NGS and exon-level microarray profiling in an accredited laboratory.
4
Bioinformatics & ACMG Curation
Variants are classified by medical geneticists against international databases (ClinVar, NCCN, ESMO).
5
Secure Digital Report
Receive your encrypted clinical report with specific organ surveillance recommendations.
Test Pricing
Comprehensive panel, full clinical support
Most Popular
Hereditary Cancer Panel
$1,490
- Dual NGS Whole Exome + Exon-level CMA
- Screening across 50+ hereditary cancer syndromes
- Comprehensive clinical report with surveillance timelines
- Turnaround time: 4–6 weeks
- Pharmacogenomics for chemotherapy tolerance included
- DNA biobanking & long-term cryopreservation
При заказе услуги из регионов перед оплатой напишите нашей поддержке: info@omninome.com или @omninome_support
Sample Clinical Report
Review an example of our comprehensive hereditary oncology report, variant classifications, and surveillance guidelines.
Expert Clinical Consultations
Clinical Geneticist
Variant interpretation, penetrance evaluation, and cascade testing strategy for relatives.
Schedule ConsultationMedical Oncologist
Personalized organ surveillance plans, chemoprevention options, and clinical staging advice.
Schedule ConsultationClinical consultations are available independently from the test package.
Why Patients Trust Omninome
Dual-Platform Technology
NGS Exome combined with high-density Exon Microarray ensures zero blind spots in coding regions and structural variations.
50+ High-Penetrance Syndromes
Covers the full spectrum of hereditary cancer guidelines recommended by NCCN, ESMO, and ASCO.
Integrated Pharmacogenomics
Actionable data on chemotherapy tolerance and supportive medications included at no extra charge.
Genomics Explained in Clear, Actionable Terms
All your clinical test results are synthesized in one secure portal, while our AI assistant clarifies complex terminology and variant annotations — empowering you to collaborate effectively with your healthcare providers.
1
Client Portal
All reports and genomic findings in a single dashboard: actionable health priorities and full variant details.
2
AI Genetic Assistant Nome
Context-aware answers tailored to your genomic data: clear clinical explanations and key questions for your physician.
3
Interactive Reports Beyond Static PDFs
Engage dynamically with your findings: filter by clinical relevance, navigate risk profiles, and prepare for doctor visits.
Expert Medical Team
Dr. Polina Shilo, MD
Medical Oncologist, ESMO Certified
Certified by the European Society for Medical Oncology (ESMO). Specializes in cancer genetics, molecular tumor boards, and evidence-based diagnostic surveillance.
Dr. Irina Zhegulina, MD
Clinical Geneticist, Co-founder
Specialist in medical genetics and hereditary syndrome diagnostics. Co-developed Omninome dual NGS+CMA methodology.
Часто задаваемые вопросы
Ready to understand your genetic cancer risks?
Undergo comprehensive hereditary cancer screening and receive an actionable clinical report with personalized surveillance protocols.
Order Test for $1,490